Clinical Report: CYP27B1 as a Key Factor in Tumor Advancement in HNSCC
Overview
This study identifies CYP27B1 as a significant factor in the progression of head and neck squamous cell carcinoma (HNSCC) through folate metabolism. The developed folate metabolism–associated gene signature (FMRG_score) serves as an independent prognostic indicator and correlates with immune landscape alterations.
Background
HNSCC is characterized by high recurrence rates and poor survival outcomes, highlighting the need for reliable biomarkers for risk assessment and treatment guidance. Folate metabolism has been implicated in tumorigenesis, yet its role in HNSCC prognosis and immune response remains unclear. Understanding these mechanisms could enhance patient stratification and therapeutic approaches.
Data Highlights
Parameter
Value
FMRG_score
Independent prognostic indicator
High-risk tumors
Activated oncogenic pathways
Immune infiltration
Diminished anti-tumor signals
CYP27B1 knockdown
Inhibited malignant characteristics
Cisplatin sensitivity
Improved with CYP27B1 knockdown
Key Findings
The FMRG_score effectively classifies HNSCC patients into distinct survival cohorts.
High FMRG_score correlates with reduced anti-tumor immune infiltration and an immunosuppressive tumor microenvironment.
CYP27B1 is identified as a key factor in tumor advancement and chemoresistance.
Functional enrichment analyses reveal activation of oncogenic pathways in high-risk tumors.
Knockdown of CYP27B1 enhances sensitivity to cisplatin treatment.
Clinical Implications
The FMRG_score can be utilized as a prognostic tool to guide treatment decisions in HNSCC patients. Additionally, targeting CYP27B1 may improve therapeutic responses, particularly in patients exhibiting chemoresistance.
Conclusion
The findings underscore the importance of folate metabolism in HNSCC progression and suggest that the FMRG_score could be a valuable biomarker for patient stratification and treatment planning.
